DICE — Dice Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $2.27bn
- $1.72bn
Annual income statement for Dice Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 5.78 | 0.863 | 1.13 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 19.3 | 24.6 | 48.7 | 88.4 |
| Operating Profit | -13.5 | -23.7 | -47.6 | -88.4 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -12.9 | -23.7 | -49 | -83.9 |
| Net Income After Taxes | -12.9 | -23.7 | -49 | -83.9 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -12.9 | -23.7 | -49 | -83.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -12.9 | -23.7 | -49 | -83.9 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.334 | -0.653 | -1.28 | -2.12 |
| Dividends per Share |